RAPT Therapeutics, Inc. financial data

Symbol
RAPT on Nasdaq
Industry
Pharmaceutical Preparations
Location
561 Eccles Avenue, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
FLX Bio, Inc. (to 1/2/2019)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 641 % -34.6%
Debt-to-equity 20.2 % +46.6%
Return On Equity -98.9 % -56.6%
Return On Assets -82.2 % -48.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 132M shares +279%
Common Stock, Shares, Outstanding 132M shares +284%
Entity Public Float 75M USD -81.2%
Common Stock, Value, Issued 13K USD +333%
Weighted Average Number of Shares Outstanding, Basic 40.8M shares +6.32%
Weighted Average Number of Shares Outstanding, Diluted 40.8M shares +6.32%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 107M USD +6.15%
General and Administrative Expense 28.9M USD +10.8%
Operating Income (Loss) -136M USD -7.11%
Nonoperating Income (Expense) 6.24M USD -39.2%
Net Income (Loss) Attributable to Parent -130M USD -11.2%
Earnings Per Share, Basic -3.19 USD/shares -4.59%
Earnings Per Share, Diluted -3.19 USD/shares -4.59%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 170M USD +258%
Marketable Securities, Current 61.3M USD -44.9%
Cash, Cash Equivalents, and Short-term Investments 231M USD +45.4%
Assets, Current 235M USD +45.4%
Property, Plant and Equipment, Net 1.37M USD -44.2%
Operating Lease, Right-of-Use Asset 3.33M USD -36.2%
Other Assets, Noncurrent 389K USD -90%
Assets 240M USD +38.7%
Accounts Payable, Current 1.28M USD -75.4%
Accrued Liabilities, Current 9.6M USD -32%
Liabilities, Current 48.4M USD +121%
Operating Lease, Liability, Noncurrent 2.07M USD -53.6%
Liabilities 50.4M USD +91.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 50K USD -51.5%
Retained Earnings (Accumulated Deficit) -615M USD -26.8%
Stockholders' Equity Attributable to Parent 190M USD +29.2%
Liabilities and Equity 240M USD +38.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -27.1M USD -45.6%
Net Cash Provided by (Used in) Financing Activities 9.04M USD +7690%
Net Cash Provided by (Used in) Investing Activities 15.9M USD -37.2%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 132M shares +284%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.16M USD -132%
Deferred Tax Assets, Valuation Allowance 135M USD +26.2%
Deferred Tax Assets, Gross 135M USD +25.6%
Operating Lease, Liability 4.49M USD -35%
Payments to Acquire Property, Plant, and Equipment 105K USD -86.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -130M USD -11.4%
Lessee, Operating Lease, Liability, to be Paid 4.8M USD -37.3%
Property, Plant and Equipment, Gross 11.4M USD -3.11%
Operating Lease, Liability, Current 2.42M USD -1.06%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.14M USD -19.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.66M USD -6.76%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 307K USD -59%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.14M USD -19.7%
Deferred Tax Assets, Operating Loss Carryforwards 67.6M USD +16%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 5.58M USD +19.4%
Operating Lease, Payments 600K USD +20%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 19.9M USD +16.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%